Averroes Pharmaceuticalssdn BHD MLY Pharmaceutical Import Profile — Malaysia (DGFT 2022–2026)

Name: Averroes Pharmaceuticalssdn BHD MLY Pharmaceutical Import Records from India — 2 Products, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Averroes Pharmaceuticalssdn BHD MLY — Pharmaceutical Importer Profile (2026) | 2 Products, $2.5M Trade | TransData Nexus

Averroes Pharmaceuticalssdn BHD MLY

Pharmaceutical Importer · Malaysia · Antibiotics Focus · $2.5M Total Trade · DGFT Verified

Averroes Pharmaceuticalssdn BHD MLY is a pharmaceutical importer based in Malaysia with a total trade value of $2.5M across 2 products in 2 therapeutic categories. Based on 72 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Averroes Pharmaceuticalssdn BHD MLY sources from 2 verified Indian suppliers, with Karnataka Antibiotics And Pharmaceuticals Limited accounting for 92.8% of imports.

Averroes Pharmaceuticalssdn BHD MLY — Import Portfolio & Supplier Network

Averroes Pharmaceuticalssdn BHD MLY import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Averroes Pharmaceuticalssdn BHD MLY?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Karnataka Antibiotics And Pharmaceuticals Limited	$2.7M	97	92.8%
Karnataka Antibiotics Pharmaceuticals Limited	$210.1K	6	7.2%

Averroes Pharmaceuticalssdn BHD MLY sources from 2 verified Indian suppliers across .

What Formulations Does Averroes Pharmaceuticalssdn BHD MLY Import?

Formulation	Value	Ships
Cloxacillin sodium for injection 500MG	$350.0K	7
Ampicillin & sulbactum for injection	$300.0K	6
Cloxacillin sodium for injection 500MG	$250.0K	5
Co-amoxiclav for injection BP 1.2GM	$200.0K	4
Ampicillin sodium for injection BP 500	$187.1K	6
Ampicillin & sulbactum for injection usp1500 MG amsubac 1.5g Each vial contains:sterile dry mixture of	$150.0K	3
Ampicillin&sulbactum for injection USP	$100.0K	2
Co-amoxiclav for injection BP 1.2 GM Each vial contains:potassium clavulanate bpequivalent to clavulanic acid 200MG	$79.0K	3
Co-amoxiclav for injection BP 1.2 GM	$78.6K	2
Ampicillin & sulbactam for injection usp1500 MG amsubac 1.5g Each vial contains:sterile dry mixture of	$69.3K	3
Benzylpenicillin for injection BP 600 MG	$64.2K	3
Ampicillin sodium for injection bp500 MG	$62.5K	2
Ampicillin sulbactum for injection usp1500 MG amsubac 1 5g Each vial contains sterile dry mixture of ampicillin sodiu	$50.0K	1
Co-amoxiclav for injection bp1.2GM eachvial contains:potassium clavulanate BP equivalent to clavulanic acid 200MG.	$50.0K	1
Ampicillin & sulbactam for INJ USP 1500MG-amsubac 1.5g Each vial contains:sterile dry mixture of ampicillin	$50.0K	1

Averroes Pharmaceuticalssdn BHD MLY imports 49 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ampicillin	Antibiotics	$2.0M	40	1.4%	7
2	Benzylpenicillin	Advanced Antibiotics	$493.9K	32	12.8%	2

Averroes Pharmaceuticalssdn BHD MLY imports 2 pharmaceutical products across 2 categories into Malaysia totaling $2.5M.

Averroes Pharmaceuticalssdn BHD MLY — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Averroes Pharmaceuticals Sdn. Bhd. is a Malaysian pharmaceutical company established in April 2001, specializing in the supply of high-quality generic medications across various therapeutic categories. The company is headquartered at 3-8-1 & 3-9-1 Block 3, Presint Alami, Worldwide Business Centre 2, Persiaran Akuatik, Section 13, 40000 Shah Alam, Selangor, Malaysia. (averroespharma.com.my) Averroes Pharmaceuticals operates as a pharmaceutical importer and distributor, focusing on both government and private sector markets within Malaysia. Since 2010, the company has expanded its international business, aiming to become a market leader in the industry by introducing new products and services. (ricebowl.my)

2Distribution Network

Averroes Pharmaceuticals maintains a comprehensive distribution network within Malaysia, supported by a warehouse facility exceeding 5,000 square feet. This infrastructure enables the company to efficiently manage inventory and fulfill orders across the country. The company's strategic location in Shah Alam, Selangor, positions it advantageously to serve both domestic and international markets, including Brunei and Singapore. (averroespharma.com.my)

3Industry Role

In Malaysia's pharmaceutical supply chain, Averroes Pharmaceuticals functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various international suppliers, notably from India. By focusing on the importation and distribution of these finished products, Averroes Pharmaceuticals plays a crucial role in ensuring the availability of quality generic medications in the Malaysian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Averroes Pharmaceuticalssdn BHD MLY

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Averroes Pharmaceuticals demonstrates a high degree of supplier concentration, with 97% of its imports sourced from Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) in India. This significant reliance on a single supplier indicates a strategic choice to maintain consistent product quality and supply chain efficiency. However, such concentration also exposes the company to potential risks associated with supplier dependency, including supply disruptions or changes in supplier terms. The stability of this relationship is evidenced by the substantial volume of shipments and the dominance of KAPL in Averroes Pharmaceuticals' import portfolio.

2Supply Chain Resilience

Averroes Pharmaceuticals' supply chain resilience is closely tied to its reliance on KAPL for the majority of its imported products. While this partnership ensures consistent product quality, the lack of diversified suppliers may pose challenges in the event of supply chain disruptions. The company's import data indicates a limited number of suppliers, suggesting a need for strategic diversification to enhance supply chain robustness. Additionally, the company's focus on importing finished pharmaceutical formulations from India suggests a streamlined supply chain with established logistics routes.

Strategic Implications

Importing Pharmaceuticals into Malaysia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malaysia

1Regulatory Authority & Framework

In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA), under the Ministry of Health, is responsible for regulating pharmaceutical products. The importation and sale of pharmaceutical products are governed by the Control of Drugs and Cosmetics Regulations 1984, which require that all pharmaceutical products be registered with the Drug Control Authority before they can be imported and sold. This regulatory framework ensures that imported pharmaceutical products meet the necessary safety, efficacy, and quality standards.

2Import Licensing & GMP

To import pharmaceutical products into Malaysia, companies must obtain an Import Licence issued by the Director of Pharmaceutical Services under Regulation 12(1)(d) of the Control of Drugs and Cosmetics Regulations 1984. Additionally, Good Manufacturing Practice (GMP) certification is mandatory for manufacturers to ensure product quality. Malaysia recognizes GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications to comply with Malaysian regulations. (npra.gov.my)

Quality & Labeling

Averroes Pharmaceuticalssdn BHD MLY — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Averroes Pharmaceuticals focuses on importing antibiotics, particularly ampicillin and benzylpenicillin, which constitute the majority of its import portfolio. This strategic emphasis aligns with the high demand for antibiotics in Malaysia, driven by the need to address various bacterial infections. The company's commitment to expanding its product portfolio to include new chemical entities (NCEs) and biologic products since 2016 indicates a proactive approach to meeting evolving market demands and enhancing treatment options for patients. (averroespharma.com.my)

2Sourcing Profile

Averroes Pharmaceuticals primarily sources generic drugs from India, focusing on finished pharmaceutical formulations. This sourcing strategy allows the company to offer cost-effective alternatives to branded medications while maintaining quality standards. The company's import data reveals a preference for antibiotics, reflecting the therapeutic areas with the highest demand in the Malaysian market.

3Market Positioning

Based on its product mix, Averroes Pharmaceuticals serves multiple segments of the Malaysian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's focus on both government and private sector markets positions it as a versatile supplier capable of meeting diverse healthcare needs across the country.

Seller's Guide — How to Become a Supplier to Averroes Pharmaceuticalssdn BHD MLY

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Malaysian market by partnering with Averroes Pharmaceuticals. The company's current sourcing pattern indicates a need for supplier diversification to enhance supply chain resilience. Indian exporters can leverage this opportunity by ensuring compliance with Malaysian regulatory requirements, obtaining necessary certifications, and meeting the quality standards expected by Averroes Pharmaceuticals.

2Requirements & Qualifications

Indian exporters seeking to supply Averroes Pharmaceuticals and the Malaysian market must obtain GMP certifications recognized by Malaysian authorities, such as WHO GMP or PIC/S. Additionally, they must ensure that their products are registered with the Drug Control Authority in Malaysia and comply with all labeling and packaging requirements, including the use of the Malay language. Adherence to these standards is essential for successful market entry.

3How to Approach

Frequently Asked Questions — Averroes Pharmaceuticalssdn BHD MLY

What products does Averroes Pharmaceuticalssdn BHD MLY import from India?

Averroes Pharmaceuticalssdn BHD MLY imports 2 pharmaceutical products across 2 categories. Top imports: Ampicillin ($2.0M), Benzylpenicillin ($493.9K).

Who supplies pharmaceuticals to Averroes Pharmaceuticalssdn BHD MLY from India?

Averroes Pharmaceuticalssdn BHD MLY sources from 2 verified Indian suppliers. The primary supplier is Karnataka Antibiotics And Pharmaceuticals Limited (92.8% of imports, $2.7M).

What is Averroes Pharmaceuticalssdn BHD MLY's total pharmaceutical import value?

Averroes Pharmaceuticalssdn BHD MLY's total pharmaceutical import value from India is $2.5M, based on 72 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Averroes Pharmaceuticalssdn BHD MLY focus on?

Averroes Pharmaceuticalssdn BHD MLY imports across 2 categories. The largest: Antibiotics (80.2%), Advanced Antibiotics (19.8%).

Get Full Averroes Pharmaceuticalssdn BHD MLY Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.